Gami Apoor S, Caples Sean M, Somers Virend K
Department of Medicine, Mayo Medical School, Rochester, MN, USA.
Endocrinol Metab Clin North Am. 2003 Dec;32(4):869-94. doi: 10.1016/s0889-8529(03)00069-0.
There is a very high prevalence of OSA in obese individuals and a high prevalence of obesity in patients with OSA. The pathophysiology of OSA is intimately linked to obesity. Anatomic and functional considerations of the pharyngeal airway, the CNS, central obesity, and leptin likely interact in the development of OSA in obese individuals. OSA may itself predispose individuals to worsening obesity because of sleep deprivation, daytime somnolence, and disrupted metabolism. The diagnosis of OSA requires the clinician's awareness of its potential to cause a spectrum of acute and chronic neurocognitive, psychiatric, and nonspecific symptoms in patients who may be unaware that their sleep is disturbed. Symptoms and examination findings help predict which obese individuals have OSA, and polysomnography is the gold standard by which to make the diagnosis and assess the effects of treatment. Numerous disease states are associated with both OSA and obesity, and it is becoming clear that the relationships are mediated by complex interrelated mechanisms. Common diseases and disease mechanisms in OSA and obesity suggest that conditions related to obesity may be better managed if patients, particularly those who are morbidly obese, are evaluated and treated for previously undiagnosed OSA. OSA is cured in only specific cases with craniofacial or upper airway surgery, and the general application of UVP is not efficacious. OSA also can be cured with sufficient lifestyle-mediated or surgical weight loss; however, in the absence of long-term weight maintenance, OSA returns with weight gain. Although not curative, nasal CPAP is the initial treatment of choice for most patients because of its noninvasive approach and technical efficacy. It is limited, however, by patient acceptance and long-term compliance. Advances in mask comfort and use of humidified air should increase its acceptance. Future management strategies include newer generations of positive airway devices that automatically titrate pressures (which are not yet recommended by expert organizations) and multidisciplinary approaches to managing the care of patients with OSA.
肥胖个体中阻塞性睡眠呼吸暂停(OSA)的患病率非常高,而OSA患者中肥胖的患病率也很高。OSA的病理生理学与肥胖密切相关。咽气道、中枢神经系统、中心性肥胖和瘦素的解剖学及功能因素可能在肥胖个体OSA的发生发展中相互作用。由于睡眠剥夺、日间嗜睡和代谢紊乱,OSA本身可能使个体更容易肥胖。OSA的诊断需要临床医生意识到其在可能未意识到睡眠受到干扰的患者中引发一系列急性和慢性神经认知、精神及非特异性症状的可能性。症状和检查结果有助于预测哪些肥胖个体患有OSA,而多导睡眠图是进行诊断和评估治疗效果的金标准。许多疾病状态与OSA和肥胖均相关,并且越来越清楚的是,这些关系是由复杂的相互关联机制介导的。OSA和肥胖中的常见疾病及疾病机制表明,如果对患者,尤其是那些病态肥胖的患者进行评估并治疗先前未诊断出的OSA,与肥胖相关的疾病可能会得到更好的管理。OSA仅在特定的颅面或上气道手术病例中可治愈,而悬雍垂腭咽成形术(UVP)的普遍应用并不有效。通过足够的生活方式介导的减重或手术减重也可以治愈OSA;然而,如果不能长期维持体重,OSA会随着体重增加而复发。尽管不能治愈,但由于其无创性和技术有效性,鼻持续气道正压通气(CPAP)是大多数患者的初始治疗选择。然而,它受到患者接受度和长期依从性的限制。面罩舒适度的提高和湿化空气的使用应会增加其接受度。未来的管理策略包括新一代能自动调节压力的气道正压通气设备(专家组织尚未推荐)以及管理OSA患者护理的多学科方法。